25TFM-NBOMe

25TFM-NBOMe
Clinical data
Other names	NBOMe-2C-TFM; 2C-TFM-NBOMe; Cimbi-138
Identifiers
	IUPAC name 2-(4-trifluoromethyl-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine;
CAS Number	1027161-33-6 ;
PubChem CID	10067667;
ChemSpider	8243207 ;
UNII	X3V8LI2TUV;
CompTox Dashboard (EPA)	DTXSID40435135 ;
Chemical and physical data
Formula	C19H22F3NO3
Molar mass	369.384 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES FC(F)(F)c1c(OC)cc(c(OC)c1)CCNCc2ccccc2OC;
	InChI InChI=1S/C19H22F3NO3/c1-24-16-7-5-4-6-14(16)12-23-9-8-13-10-18(26-3)15(19(20,21)22)11-17(13)25-2/h4-7,10-11,23H,8-9,12H2,1-3H3 ; Key:FBHVTQIAHOTPAM-UHFFFAOYSA-N ;
	(what is this?) (verify)

25TFM-NBOMe (also known as NBOMe-2C-TFM, 2C-TFM-NBOMe, and Cimbi-138) is a derivative of the phenethylamine hallucinogen 2C-TFM, discovered in 2004 by Ralf Heim at the Free University of Berlin. It acts as a potent partial agonist for the 5-HT_2A receptor, though its relative potency is disputed, with some studies finding it to be of lower potency than 25I-NBOMe, while others show it to be of similar or higher potency, possibly because of differences in the assay used. 2C-TFM-NB2OMe can be taken to produce psychedelic effects similar to 2C-I-NB2OMe and 2C-D-NB2OMe.